Seraxis Takes Its Islet Cell Tech Into The Clinic

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

Embryonic stem cells , Cellular therapy , Regeneration , Disease treatment , 3d illustration - Illustration — Stem cells

Several companies are developing islet cell-based therapies for type 1 diabetes, and all face the same two problems: avoiding the host’s immune response to foreign tissue, and manufacturing at scale.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis $23bn US Investment Is Music To Trump’s Ears

11 Apr 2025

• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

10 Apr 2025

• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off